The estimated Net Worth of Spiro Kevin Sakiris is at least $289 millier dollars as of 22 June 2022. Mr Sakiris owns over 5,000 units of GBS stock worth over $23,607 and over the last 4 years he sold GBS stock worth over $0. In addition, he makes $265,584 as Chief Financial Officer at GBS.
Sign up
Mr Law GBS stock SEC Form 4 insiders trading
Mr has made over 4 trades of the GBS stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of GBS stock worth $3,250 on 22 June 2022.
The largest trade he's ever made was buying 15,970 units of GBS stock on 17 June 2022 worth over $9,742. On average, Mr trades about 6,828 units every 67 days since 2021. As of 22 June 2022 he still owns at least 50,228 units of GBS stock.
You can see the complete history of Mr Sakiris stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law biography
Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law is the Chief Financial Officer at GBS.
What is the salary of Mr Law?
As the Chief Financial Officer of GBS, the total compensation of Mr Law at GBS is $265,584. There are 1 executives at GBS getting paid more, with Harry Simeonidis having the highest compensation of $302,599.
How old is Mr Law?
Mr Law is 59, he's been the Chief Financial Officer of GBS since . There are 1 older and 3 younger executives at GBS. The oldest executive at GBS Inc. is Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D., 64, who is the Interim CEO & Chairman.
What's Mr Law's mailing address?
Spiro's mailing address filed with the SEC is C/O GBS INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK, NY, 10019.
Insiders trading at GBS
Over the last 4 years, insiders at GBS have traded over $6,891,194 worth of GBS stock and bought 51,106 units worth $85,007 . The most active insiders traders include Science Biosensor Diagnosti..., Spiro Kevin Sakiris et Tom Parmakellis. On average, GBS executives and independent directors trade stock every 12 days with the average trade being worth of $51,467. The most recent stock trade was executed by Spiro Kevin Sakiris on 22 June 2022, trading 5,000 units of GBS stock currently worth $3,250.
What does GBS do?
GBS Inc. operates as a biosensor diagnostic technology company. It offers Saliva Glucose Biosensor that uses saliva to measure glucose non-invasively. The company also focuses on developing COV2 test, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumour markers, hormones, and nucleic acid diagnostic modalities. It has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
What does GBS's logo look like?
Complete history of Mr Sakiris stock trades at GBS
GBS executives and stock owners
GBS executives and other stock owners filed with the SEC include:
-
Harry Simeonidis,
Pres of Asia Pacific - Sales & Marketing -
Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law,
Chief Financial Officer -
Spiro Kevin Sakiris C.A., B.Bus, Dip Law, CA,
Chief Financial Officer -
Dr. Stephen Constantine Boyages M.D., MBBS, Ph.D.,
Interim CEO & Chairman -
Joe Roxburgh,
Non-Executive Director -
Steven Ross,
Non-Executive Director -
Christopher Foulds,
Non-Executive Director -
Graham Tuckwell,
Non-Executive Chairman of the Board -
Alex Arzeno,
VP of Investor Relations -
Victoria Gavrilenko,
Operations Mang. -
Spiro Kevin Sakiris,
Chief Financial Officer -
Harry Simeonidis,
President -
Lawrence B Fisher,
Director -
George Margelis,
Director -
Jonathan Scott Hurd,
Director -
Steven Constantine Boyages,
Interim CEO and Chairperson -
Tom Parmakellis,
Director -
Science Biosensor Diagnosti...,
-
Victoria Gavrilenko,
Director -
Christopher Towers,
Director